Erythropoietic regulators of iron metabolism

Free Radical Biology and Medicine

Volumn 133, Issue , 2019, Pages 69-74

  Ganz, Tomas ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anemia; Erythroferrone; Erythropoiesis; Hepcidin; Iron

Indexed keywords

FERROPORTIN; GROWTH DIFFERENTIATION FACTOR 15; HEPCIDIN; MATRIPTASE; MONOCLONAL ANTIBODY; PROTEIN ERYTHROFERRONE; PROTEIN TMPRSS6; UNCLASSIFIED DRUG; BONE MORPHOGENETIC PROTEIN; ERFE PROTEIN, HUMAN; ERYTHROPOIETIN; IRON; PEPTIDE HORMONE;

ANEMIA; BLEEDING; ENZYME ACTIVITY; ENZYME MECHANISM; ENZYME REPRESSION; ERYTHROPOIESIS; HUMAN; IRON HOMEOSTASIS; IRON METABOLISM; IRON OVERLOAD; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; GENETICS; LIVER CELL; MACROPHAGE; METABOLISM; PATHOLOGY;

ANEMIA; BONE MORPHOGENETIC PROTEINS; ERYTHROPOIESIS; ERYTHROPOIETIN; HEPATOCYTES; HEPCIDINS; HUMANS; IRON; IRON OVERLOAD; MACROPHAGES; PEPTIDE HORMONES;

EID: 85049606210     PISSN: 08915849     EISSN: 18734596     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2018.07.003     Document Type: Review

References (61)

1. Glomski, C.A., Tamburlin, J., The phylogenetic odyssey of the erythrocyte. I. Hemoglobin: the universal respiratory pigment. Histol. Histopathol. 4:4 (1989), 509–514.
2. Giblett, E.R., Coleman, D.H., Pirzio-Biroli, G., Donohue, D.M., Motulsky, A.G., Finch, C.A., Erythrokinetics: quantitative measurements of red cell production and destruction in normal subjects and patients with anemia. Blood 11:4 (1956), 291–309.
3. Stefanova, D., Raychev, A., Deville, J., Humphries, R., Campeau, S., Ruchala, P., Nemeth, E., Ganz, T., Bulut, Y., Hepcidin protects against lethal E. coli sepsis in mice inoculated with isolates from septic patients. Infect. Immun., 2018.
4. Brissot, P., Ropert, M., Le, L.C., Loreal, O., Non-transferrin bound iron: a key role in iron overload and iron toxicity. Biochim. Biophys. Acta 1820:3 (2012), 403–410.
5. Finch, C.A., Some quantitative aspects of erythropoiesis. Ann. N. Y. Acad. Sci. 77 (1959), 410–416.
6. Bullock, G.C., Delehanty, L.L., Talbot, A.L., Gonias, S.L., Tong, W.H., Rouault, T.A., Dewar, B., Macdonald, J.M., Chruma, J.J., Goldfarb, A.N., Iron control of erythroid development by a novel aconitase-associated regulatory pathway. Blood 116:1 (2010), 97–108.
7. Finch, C., Regulators of iron balance in humans. Blood 84:6 (1994), 1697–1702.
8. Nemeth, E., Tuttle, M.S., Powelson, J., Vaughn, M.B., Donovan, A., Ward, D.M., Ganz, T., Kaplan, J., Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306:5704 (2004), 2090–2093.
9. Glomski, C.A., Tamburlin, J., Chainani, M., The phylogenetic odyssey of the erythrocyte. III. Fish, the lower vertebrate experience. Histol. Histopathol. 7:3 (1992), 501–528.
10. Aschemeyer, S., Qiao, B., Stefanova, D., Valore, E.V., Sek, A.C., Ruwe, T.A., Vieth, K.R., Jung, G., Casu, C., Rivella, S., Jormakka, M., Mackenzie, B., Ganz, T., Nemeth, E., Structure-function analysis of ferroportin defines the binding site and an alternative mechanism of action of hepcidin. Blood, 2017.
11. Rivera, S., Nemeth, E., Gabayan, V., Lopez, M.A., Farshidi, D., Ganz, T., Synthetic hepcidin causes rapid dose-dependent hypoferremia and is concentrated in ferroportin-containing organs. Blood 106:6 (2005), 2196–2199.
12. Ramos, E., Ruchala, P., Goodnough, J.B., Kautz, L., Preza, G.C., Nemeth, E., Ganz, T., Minihepcidins prevent iron overload in a hepcidin-deficient mouse model of severe hemochromatosis. Blood 120:18 (2012), 3829–3836.
13. Corradini, E., Meynard, D., Wu, Q., Chen, S., Ventura, P., Pietrangelo, A., Babitt, J.L., Serum and liver iron differently regulate the bone morphogenetic protein 6 (BMP6)-SMAD signaling pathway in mice. Hepatology 54:1 (2011), 273–284.
14. Corradini, E., Garuti, C., Montosi, G., Ventura, P., Andriopoulos, B. Jr., Lin, H.Y., Pietrangelo, A., Babitt, J.L., Bone morphogenetic protein signaling is impaired in an HFE knockout mouse model of hemochromatosis. Gastroenterology 137:4 (2009), 1489–1497.
15. Babitt, J.L., Huang, F.W., Xia, Y., Sidis, Y., Andrews, N.C., Lin, H.Y., Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance. J. Clin. Invest. 117:7 (2007), 1933–1939.
16. Canali, S., Zumbrennen-Bullough, K.B., Core, A.B., Wang, C.Y., Nairz, M., Bouley, R., Swirski, F.K., Babitt, J.L., Endothelial cells produce bone morphogenetic protein 6 required for iron homeostasis in mice. Blood 129:4 (2017), 405–414.
17. Koch, P.S., Olsavszky, V., Ulbrich, F., Sticht, C., Demory, A., Leibing, T., Henzler, T., Meyer, M., Zierow, J., Schneider, S., Breitkopf-Heinlein, K., Gaitantzi, H., Spencer-Dene, B., Arnold, B., Klapproth, K., Schledzewski, K., Goerdt, S., Geraud, C., Angiocrine Bmp2 signaling in murine liver controls normal iron homeostasis. Blood 129:4 (2017), 415–419.
18. Ramos, E., Kautz, L., Rodriguez, R., Hansen, M., Gabayan, V., Ginzburg, Y., Roth, M.P., Nemeth, E., Ganz, T., Evidence for distinct pathways of hepcidin regulation by acute and chronic iron loading in mice. Hepatology 53:4 (2011), 1333–1341.
19. Mendel, G.A., Studies on iron absorption. I. The relationships between the rate of erythropoiesis, hypoxia and iron absorption. Blood 18:6 (1961), 727–736.
20. Nicolas, G., Chauvet, C., Viatte, L., Danan, J.L., Bigard, X., Devaux, I., Beaumont, C., Kahn, A., Vaulont, S., The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J. Clin. Invest. 110:7 (2002), 1037–1044.
21. Pak, M., Lopez, M.A., Gabayan, V., Ganz, T., Rivera, S., Suppression of hepcidin during anemia requires erythropoietic activity. Blood 108:12 (2006), 3730–3735.
22. Vokurka, M., Krijt, J., Sulc, K., Necas, E., Hepcidin mRNA levels in mouse liver respond to inhibition of erythropoiesis. Physiol. Res. 55:6 (2006), 667–674.
23. Liu, Q., Davidoff, O., Niss, K., Haase, V.H., Hypoxia-inducible factor regulates hepcidin via erythropoietin-induced erythropoiesis. J. Clin. Invest. 122:12 (2012), 4635–4644.
24. Ashby, D.R., Gale, D.P., Busbridge, M., Murphy, K.G., Duncan, N.D., Cairns, T.D., Taube, D.H., Bloom, S.R., Tam, F.W., Chapman, R., Maxwell, P.H., Choi, P., Erythropoietin administration in humans causes a marked and prolonged reduction in circulating hepcidin. Haematologica, 2009.
25. Papanikolaou, G., Tzilianos, M., Christakis, J.I., Bogdanos, D., Tsimirika, K., MacFarlane, J., Goldberg, Y.P., Sakellaropoulos, N., Ganz, T., Nemeth, E., Hepcidin in iron overload disorders. Blood 105:10 (2005), 4103–4105.
26. Origa, R., Galanello, R., Ganz, T., Giagu, N., Maccioni, L., Faa, G., Nemeth, E., Liver iron concentrations and urinary hepcidin in beta-thalassemia. Haematologica 92:5 (2007), 583–588.
27. Kearney, S.L., Nemeth, E., Neufeld, E.J., Thapa, D., Ganz, T., Weinstein, D.A., Cunningham, M.J., Urinary hepcidin in congenital chronic anemias. Pediatr. Blood Cancer 48:1 (2007), 57–63.
28. Tanno, T., Bhanu, N.V., Oneal, P.A., Goh, S.H., Staker, P., Lee, Y.T., Moroney, J.W., Reed, C.H., Luban, N.L., Wang, R.H., Eling, T.E., Childs, R., Ganz, T., Leitman, S.F., Fucharoen, S., Miller, J.L., High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat. Med. 13:9 (2007), 1096–1101.
29. Tamary, H., Shalev, H., Perez-Avraham, G., Zoldan, M., Levi, I., Swinkels, D.W., Tanno, T., Miller, J.L., Elevated growth differentiation factor 15 expression in patients with congenital dyserythropoietic anemia type I. Blood 112:13 (2008), 5241–5244.
30. Casanovas, G., Swinkels, D.W., Altamura, S., Schwarz, K., Laarakkers, C.M., Gross, H.J., Wiesneth, M., Heimpel, H., Muckenthaler, M.U., Growth differentiation factor 15 in patients with congenital dyserythropoietic anaemia (CDA) type II. J. Mol. Med. 89:8 (2011), 811–816.
31. Casanovas, G., Vujic Spasic, M., Casu, C., Rivella, S., Strelau, J., Unsicker, K., Muckenthaler, M.U., The murine growth differentiation factor 15 is not essential for systemic iron homeostasis in phlebotomized mice. Haematologica 98:3 (2013), 444–447.
32. Mirciov, C.S., Wilkins, S.J., Dunn, L.A., Anderson, G.J., Frazer, D.M., Characterization of putative erythroid regulators of hepcidin in mouse models of anemia. PLoS One, 12(1), 2017, e0171054.
33. Ashby, D.R., Gale, D.P., Busbridge, M., Murphy, K.G., Duncan, N.D., Cairns, T.D., Taube, D.H., Bloom, S.R., Tam, F.W., Chapman, R., Maxwell, P.H., Choi, P., Erythropoietin administration in humans causes a marked and prolonged reduction in circulating hepcidin. Haematologica 95:3 (2010), 505–508.
34. Robach, P., Recalcati, S., Girelli, D., Campostrini, N., Kempf, T., Wollert, K.C., Corbella, M., Santambrogio, P., Perbellini, L., Brasse-Lagnel, C., Christensen, B., Moutereau, S., Lundby, C., Cairo, G., Serum hepcidin levels and muscle iron proteins in humans injected with low- or high-dose erythropoietin. Eur. J. Haematol. 91:1 (2013), 74–84.
35. Laine, F., Laviolle, B., Ropert, M., Bouguen, G., Morcet, J., Hamon, C., Massart, C., Westermann, M., Deugnier, Y., Loreal, O., Early effects of erythropoietin on serum hepcidin and serum iron bioavailability in healthy volunteers. Eur. J. Appl. Physiol., 2011.
36. Artimo, P., Jonnalagedda, M., Arnold, K., Baratin, D., Csardi, G., de Castro, E., Duvaud, S., Flegel, V., Fortier, A., Gasteiger, E., Grosdidier, A., Hernandez, C., Ioannidis, V., Kuznetsov, D., Liechti, R., Moretti, S., Mostaguir, K., Redaschi, N., Rossier, G., Xenarios, I., Stockinger, H., ExPASy: SIB bioinformatics resource portal. Nucleic Acids Res. 40:Web Server issue (2012), W597–W603.
37. Kautz, L., Jung, G., Valore, E.V., Rivella, S., Nemeth, E., Ganz, T., Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat. Genet. 46:7 (2014), 678–684.
38. Gurieva, I., Frydlova, J., Rychtarcikova, Z., Vokurka, M., Truksa, J., Krijt, J., Erythropoietin administration increases splenic erythroferrone protein content and liver TMPRSS6 protein content in rats. Blood Cells Mol. Dis. 64 (2017), 1–7.
39. Shapiro, L., Scherer, P.E., The crystal structure of a complement-1q family protein suggests an evolutionary link to tumor necrosis factor. Curr. Biol. 8:6 (1998), 335–340.
40. Kautz, L., Jung, G., Du, X., Gabayan, V., Chapman, J., Nasoff, M., Nemeth, E., Ganz, T., Erythroferrone contributes to hepcidin suppression and iron overload in a mouse model of beta-thalassemia. Blood 126:17 (2015), 2031–2037.
41. Taylor, M., Qu, A., Anderson, E.R., Matsubara, T., Martin, A., Gonzalez, F.J., Shah, Y.M., Hypoxia-inducible factor-2alpha mediates the adaptive increase of intestinal ferroportin during iron deficiency in mice. Gastroenterology 140:7 (2011), 2044–2055.
42. Kautz, L., Jung, G., Nemeth, E., Ganz, T., Erythroferrone contributes to recovery from anemia of inflammation. Blood 124:16 (2014), 2569–2574.
43. Jiang, X., Gao, M., Chen, Y., Liu, J., Qi, S., Ma, J., Zhang, Z., Xu, Y., EPO-dependent induction of erythroferrone drives hepcidin suppression and systematic iron absorption under phenylhydrazine-induced hemolytic anemia. Blood Cells Mol. Dis. 58 (2016), 45–51.
44. Kim, A., Fung, E., Parikh, S.G., Valore, E.V., Gabayan, V., Nemeth, E., Ganz, T., A mouse model of anemia of inflammation: complex pathogenesis with partial dependence on hepcidin. Blood 123:8 (2014), 1129–1136.
45. Gardenghi, S., Renaud, T.M., Meloni, A., Casu, C., Crielaard, B.J., Bystrom, L.M., Greenberg-Kushnir, N., Sasu, B.J., Cooke, K.S., Rivella, S., Distinct roles for hepcidin and interleukin-6 in the recovery from anemia in mice injected with heat-killed Brucella abortus. Blood 123:8 (2014), 1137–1145.
46. Ganz, T., Jung, G., Naeim, A., Ginzburg, Y., Pakbaz, Z., Walter, P.B., Kautz, L., Nemeth, E., Immunoassay for human serum erythroferrone. Blood 130:10 (2017), 1243–1246.
47. Hanudel, M.R., Rappaport, M., Chua, K., Gabayan, V., Qiao, B., Jung, G., Salusky, I.B., Ganz, T., Nemeth, E., Levels of the erythropoietin-responsive hormone erythroferrone in mice and humans with chronic kidney disease. Haematologica 103:4 (2018), e141–e142.
48. Wang, C.Y., Core, A.B., Canali, S., Zumbrennen-Bullough, K.B., Ozer, S., Umans, L., Zwijsen, A., Babitt, J.L., Smad1/5 is required for erythropoietin-mediated suppression of hepcidin in mice. Blood 130:1 (2017), 73–83.
49. Beutler, E., Lee, P., Gelbart, T., Du, X., Beutler, B., The mask mutation identifies TMPRSS6 as an essential suppressor of hepcidin gene expression, required for normal uptake of dietary iron. ASH Annu. Meet. Abstr., 110(11), 2007, 3.
50. Finberg, K.E., Heeney, M.M., Campagna, D.R., Aydinok, Y., Pearson, H.A., Hartman, K.R., Mayo, M.M., Samuel, S.M., Strouse, J.J., Markianos, K., Andrews, N.C., Fleming, M.D., Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA). Nat. Genet. 40:5 (2008), 569–571.
51. Folgueras, A.R., de Lara, F.M., Pendas, A.M., Garabaya, C., Rodriguez, F., Astudillo, A., Bernal, T., Cabanillas, R., Lopez-Otin, C., Velasco, G., Membrane-bound serine protease matriptase-2 (Tmprss6) is an essential regulator of iron homeostasis. Blood 112:6 (2008), 2539–2545.
52. Silvestri, L., Pagani, A., Nai, A., De Domenico, I., Kaplan, J., Camaschella, C., The serine protease matriptase-2 (TMPRSS6) inhibits hepcidin activation by cleaving membrane hemojuvelin. Cell Metab. 8:6 (2008), 502–511.
53. Finberg, K.E., Whittlesey, R.L., Fleming, M.D., Andrews, N.C., Down-regulation of Bmp/Smad signaling by Tmprss6 is required for maintenance of systemic iron homeostasis. Blood 115:18 (2010), 3817–3826.
54. Wahedi, M., Wortham, A.M., Kleven, M.D., Zhao, N., Jue, S., Enns, C.A., Zhang, A.-S., Matriptase-2 suppresses hepcidin expression by cleaving multiple components of the hepcidin induction pathway. J. Biol. Chem. 292:44 (2017), 18354–18371.
55. Du, X., She, E., Gelbart, T., Truksa, J., Lee, P., Xia, Y., Khovananth, K., Mudd, S., Mann, N., Moresco, E.M., Beutler, E., Beutler, B., The serine protease TMPRSS6 is required to sense iron deficiency. Science 320:5879 (2008), 1088–1092.
56. Nai, A., Rubio, A., Campanella, A., Gourbeyre, O., Artuso, I., Bordini, J., Gineste, A., Latour, C., Besson-Fournier, C., Lin, H.Y., Coppin, H., Roth, M.P., Camaschella, C., Silvestri, L., Meynard, D., Limiting hepatic Bmp-Smad signaling by matriptase-2 is required for erythropoietin-mediated hepcidin suppression in mice. Blood 127:19 (2016), 2327–2336.
57. Nai, A., Pagani, A., Mandelli, G., Lidonnici, M.R., Silvestri, L., Ferrari, G., Camaschella, C., Deletion of TMPRSS6 attenuates the phenotype in a mouse model of beta-thalassemia. Blood 119:21 (2012), 5021–5029.
58. Guo, S., Casu, C., Gardenghi, S., Booten, S., Aghajan, M., Peralta, R., Watt, A., Freier, S., Monia, B.P., Rivella, S., Reducing TMPRSS6 ameliorates hemochromatosis and beta-thalassemia in mice. J. Clin. Invest. 123:4 (2013), 1531–1541.
59. Schmidt, P.J., Toudjarska, I., Sendamarai, A.K., Racie, T., Milstein, S., Bettencourt, B.R., Hettinger, J., Bumcrot, D., Fleming, M.D., An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe(-/-) mice and ameliorates anemia and iron overload in murine beta-thalassemia intermedia. Blood 121:7 (2013), 1200–1208.
60. Aschemeyer, S., Gabayan, V., Ganz, T., Nemeth, E., Kautz, L., Erythroferrone and matriptase-2 independently regulate hepcidin expression. Am. J. Hematol. 92:5 (2017), E61–E63.
61. Kattamis, A., Papassotiriou, I., Palaiologou, D., Apostolakou, F., Galani, A., Ladis, V., Sakellaropoulos, N., Papanikolaou, G., The effects of erythropoetic activity and iron burden on hepcidin expression in patients with thalassemia major. Haematologica 91:6 (2006), 809–812.